Cidara Therapeutics And Mundipharma Announce Positive Topline Results From The Global Phase 3 Pivotal ReSTORE Trial Of Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis; Trial Met FDA And EMA-Pre-Specified Primary Endpoints

by | Dec 14, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.